This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Our Compounds

Boehringer Ingelheim is taking on cancer through a dedicated commitment to delivering first-in-class cancer cell-directed therapies, innovative immuno-oncology strategies and smart combination approaches.

Filter by:
Phase I Phase II Phase III Approved
Cancer cell-directed and immuno-oncology therapies

ATP128 cancer vaccine

Metastatic colorectal cancer
1 Phase I

STING agonist (in preparation)

TRAILR2/CDH17 antibody (in preparation)

DLL3-CD3 bispecific antibody (in preparation)

CD73 inhibitor (in preparation)

VSV-GP oncolytic virus platform (in preparation)

MEK inhibitor (in preparation)

Combination Approaches

ATP128 cancer vaccine + PD-1 inhibitor (BI 754091)

Metastatic colorectal cancer
1 Phase I

STING agonist (in preparation) + PD-1 inhibitor (BI 754091)

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information..

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here.


Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063, BI 1361849, SOS1::KRAS inhibitor, STING agonist and TRAILR2/CDH17 antibody are investigational compounds and have not been approved. Their safety and efficacy have not been established.


Ang2, angiopoietin 2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; KRAS, Kirsten rat sarcoma; LAG-3, lymphocyte activation gene 3 protein; LRP5/6, lipoprotein receptor-related protein 5/6; MDM2, murine double minute 2 protein; mRNA, messenger ribonucleic acid; NSCLC: non-small-cell lung carcinoma; PD-1, programmed cell death protein-1; PDGFR, platelet-derived growth factor receptor; SIRPα, signal-regulatory protein alpha; SMAC, second mitochondria-derived activator of caspase; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumour necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.


© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: October 2019



Prescribing Information: GIOTRIF®. (Accessed: October 2019).


Prescribing Information: VARGATEF®. (Accessed: October 2019).

3 NCT03099174. (Accessed: October 2019).

4 NCT02123823. (Accessed: October 2019).

5 NCT03659136. (Accessed: October 2019).

6 NCT03207191. (Accessed: October 2019).

7 NCT02632721. (Accessed: October 2019).

8 NCT03013998. (Accessed: October 2019).

9 NCT03468426. (Accessed: October 2019).

10 NCT02952248. (Accessed: October 2019).

11 NCT03156114. (Accessed: October 2019).

12 NCT03780725. (Accessed: October 2019).

13 NCT03433898. (Accessed: October 2019).

14 NCT03166631. (Accessed: October 2019).

15 NCT03697304. (Accessed: October 2019).

16 NCT02674152. (Accessed: October 2019).

17 NCT02689505. (Accessed: October 2019).

18 NCT02516553. (Accessed: October 2019).

19 NCT03449381. (Accessed: October 2019).

20 NCT03604445. (Accessed: October 2019).

21 NCT04111458. (Accessed: October 2019).

22 NCT03164772. (Accessed: October 2019).


Boehringer Ingelheim. Data on file.


Boehringer Ingelheim. Data on file.